HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Devens, B. Articles by Naor, D. Search for Related Content PubMed Articles by Devens, B. Articles by Naor, D.

Immune Responses to Weakly Immunogenic Virally Induced Tumors

III. Genetically Unrestricted Cytolysis of Allogeneic Tumor Target Cells¹

From the Lautenberg Center for General and Tumor Immunology, The Hebrew University - Hadassah Medical School, Jerusalem, Israel

Abstract

Splenocytes from A mice injected with YAC-1 or RBL5 could generate, after in vitro culture with or without stimulation, a genetically nonrestricted cytotoxic response against the allogenic tumor RBL5. YAC-1 tumor is an in vitro carried tumor induced in A mice (H-2^a) by Moloney virus. RBL5 tumor is a Rauscher virus-induced tumor of C57BL/6 mice (H-2^b). These tumors cross-react serologically.

The effector cells that were generated after the in vitro cultivation recognized tumor-associated antigens on the target cells. H-2 alloantigens were not recognized by the effector cells. The effector cells that killed RBL5 tumor in a genetically nonrestricted manner were identified as T cells. The in vivo carried tumor YAC, in contrast to the in vitro carried tumor YAC-1, could not induce anti-RBL5 reactive cells in A mice. Instead, YAC tumor induced suppressor cells in A mice, which could abrogate the anti-RBL5 cytotoxic response of RBL5-primed splenocytes, but not that of YAC-1 primed splenocytes.

Footnotes

¹ This work was supported by the Leukemia Research Foundation, Inc., The Lautenberg Endowment Fund, and Concern Foundation, Los Angeles, California.

² B. Devens was supported by National Institutes of Health Fellowship 1 F32 CA06069-01, awarded by the National Cancer Institute.